198 related articles for article (PubMed ID: 35157705)
41. Indolent course of brainstem tumors with K27M-H3.3 mutation.
Baroni LV; Solano-Paez P; Nobre L; Michaeli O; Hawkins C; Laughlin S; Bartels U; Ramaswamy V; Bouffet E
Pediatr Blood Cancer; 2020 Mar; 67(3):e28102. PubMed ID: 31793190
[TBL] [Abstract][Full Text] [Related]
42. A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
DeWire M; Fuller C; Hummel TR; Chow LML; Salloum R; de Blank P; Pater L; Lawson S; Zhu X; Dexheimer P; Carle AC; Kumar SS; Drissi R; Stevenson CB; Lane A; Breneman J; Witte D; Jones BV; Leach JL; Fouladi M
J Neurooncol; 2020 Sep; 149(3):511-522. PubMed ID: 33034839
[TBL] [Abstract][Full Text] [Related]
43. Identification of new therapeutic targets and natural compounds against diffuse intrinsic pontine glioma (DIPG).
Chen J; Lin Z; Barrett L; Dai L; Qin Z
Bioorg Chem; 2020 Jun; 99():103847. PubMed ID: 32311581
[TBL] [Abstract][Full Text] [Related]
44. Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG.
Anastas JN; Zee BM; Kalin JH; Kim M; Guo R; Alexandrescu S; Blanco MA; Giera S; Gillespie SM; Das J; Wu M; Nocco S; Bonal DM; Nguyen QD; Suva ML; Bernstein BE; Alani R; Golub TR; Cole PA; Filbin MG; Shi Y
Cancer Cell; 2019 Nov; 36(5):528-544.e10. PubMed ID: 31631026
[TBL] [Abstract][Full Text] [Related]
45. Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma.
Katagi H; Takata N; Aoi Y; Zhang Y; Rendleman EJ; Blyth GT; Eckerdt FD; Tomita Y; Sasaki T; Saratsis AM; Kondo A; Goldman S; Becher OJ; Smith E; Zou L; Shilatifard A; Hashizume R
Neuro Oncol; 2021 Aug; 23(8):1348-1359. PubMed ID: 33471107
[TBL] [Abstract][Full Text] [Related]
46. Context-dependent tumor-suppressive BMP signaling in diffuse intrinsic pontine glioma regulates stemness through epigenetic regulation of CXXC5.
Sun Y; Yan K; Wang Y; Xu C; Wang D; Zhou W; Guo S; Han Y; Tang L; Shao Y; Shan S; Zhang QC; Tang Y; Zhang L; Xi Q
Nat Cancer; 2022 Sep; 3(9):1105-1122. PubMed ID: 35915262
[TBL] [Abstract][Full Text] [Related]
47. Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma.
Flannery PC; DeSisto JA; Amani V; Venkataraman S; Lemma RT; Prince EW; Donson A; Moroze EE; Hoffman L; Levy JMM; Foreman N; Vibhakar R; Green AL
Oncol Rep; 2018 Feb; 39(2):455-464. PubMed ID: 29207163
[TBL] [Abstract][Full Text] [Related]
48. Targeting DNA Repair and Survival Signaling in Diffuse Intrinsic Pontine Gliomas to Prevent Tumor Recurrence.
Sharma M; Barravecchia I; Teis R; Cruz J; Mumby R; Ziemke EK; Espinoza CE; Krishnamoorthy V; Magnuson B; Ljungman M; Koschmann C; Chandra J; Whitehead CE; Sebolt-Leopold JS; Galban S
Mol Cancer Ther; 2024 Jan; 23(1):24-34. PubMed ID: 37723046
[TBL] [Abstract][Full Text] [Related]
49. High Level Immunoglobulin Gene Expression and Reduced Intra-tumoral Bacteria Associated With the Transition from Initial to Progressive Diffuse Intrinsic Pontine Glioma.
Gozlan EC; Huda TI; Quach JU; Varkhedi M; Desantis JE; Blanck G
Anticancer Res; 2024 Jun; 44(6):2325-2333. PubMed ID: 38821589
[TBL] [Abstract][Full Text] [Related]
50. Development of a human in vitro blood-brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance.
Deligne C; Hachani J; Duban-Deweer S; Meignan S; Leblond P; Carcaboso AM; Sano Y; Shimizu F; Kanda T; Gosselet F; Dehouck MP; Mysiorek C
Fluids Barriers CNS; 2020 Jun; 17(1):37. PubMed ID: 32487241
[TBL] [Abstract][Full Text] [Related]
51. Characterizing the pharmacokinetics of panobinostat in a non-human primate model for the treatment of diffuse intrinsic pontine glioma.
Rodgers LT; Lester McCully CM; Odabas A; Cruz R; Peer CJ; Figg WD; Warren KE
Cancer Chemother Pharmacol; 2020 Apr; 85(4):827-830. PubMed ID: 31894347
[TBL] [Abstract][Full Text] [Related]
52. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma.
Grasso CS; Tang Y; Truffaux N; Berlow NE; Liu L; Debily MA; Quist MJ; Davis LE; Huang EC; Woo PJ; Ponnuswami A; Chen S; Johung TB; Sun W; Kogiso M; Du Y; Qi L; Huang Y; Hütt-Cabezas M; Warren KE; Le Dret L; Meltzer PS; Mao H; Quezado M; van Vuurden DG; Abraham J; Fouladi M; Svalina MN; Wang N; Hawkins C; Nazarian J; Alonso MM; Raabe EH; Hulleman E; Spellman PT; Li XN; Keller C; Pal R; Grill J; Monje M
Nat Med; 2015 Jun; 21(6):555-9. PubMed ID: 25939062
[TBL] [Abstract][Full Text] [Related]
53. A 2-year-old patient with a diffuse intrinsic pontine glioma and radiation-induced moyamoya syndrome.
Iizuka A; Shiba N; Shimosato Y; Yoshitomi M; Nakamura T; Miyatake S; Takano Y; Sasaki K; Takeuchi M; Murata H; Yamamoto T; Matsumoto N; Ito S
Pediatr Blood Cancer; 2020 Oct; 67(10):e28618. PubMed ID: 33460219
[No Abstract] [Full Text] [Related]
54. Developing H3K27M mutant selective radiosensitization strategies in diffuse intrinsic pontine glioma.
Parsels LA; Wahl DR; Koschmann C; Morgan MA; Zhang Q
Neoplasia; 2023 Mar; 37():100881. PubMed ID: 36724689
[TBL] [Abstract][Full Text] [Related]
55. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
[TBL] [Abstract][Full Text] [Related]
56. TSPO PET Imaging as a Potent Non-Invasive Biomarker for Diffuse Intrinsic Pontine Glioma in a Patient-Derived Orthotopic Rat Model.
Chevaleyre C; Kereselidze D; Caillé F; Tournier N; Olaciregui NG; Winkeler A; Declèves X; Jego B; Cisternino S; Auvity S; Truillet C
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293329
[TBL] [Abstract][Full Text] [Related]
57. OLIG2 maintenance is not essential for diffuse intrinsic pontine glioma cell line growth but regulates tumor phenotypes.
Liao Y; Luo Z; Deng Y; Zhang F; Rao R; Wang J; Xu L; Kumar SS; Sengupta S; DeWire-Schottmiller M; Berry K; Garrett M; Fouladi M; Drissi R; Lu QR
Neuro Oncol; 2021 Jul; 23(7):1183-1196. PubMed ID: 33539525
[TBL] [Abstract][Full Text] [Related]
58. Pediatric diffuse intrinsic pontine glioma: where do we stand?
Rashed WM; Maher E; Adel M; Saber O; Zaghloul MS
Cancer Metastasis Rev; 2019 Dec; 38(4):759-770. PubMed ID: 31802357
[TBL] [Abstract][Full Text] [Related]
59. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory.
Ausejo-Mauleon I; Labiano S; de la Nava D; Laspidea V; Zalacain M; Marrodán L; García-Moure M; González-Huarriz M; Hervás-Corpión I; Dhandapani L; Vicent S; Collantes M; Peñuelas I; Becher OJ; Filbin MG; Jiang L; Labelle J; de Biagi-Junior CAO; Nazarian J; Laternser S; Phoenix TN; van der Lugt J; Kranendonk M; Hoogendijk R; Mueller S; De Andrea C; Anderson AC; Guruceaga E; Koschmann C; Yadav VN; Gállego Pérez-Larraya J; Patiño-García A; Pastor F; Alonso MM
Cancer Cell; 2023 Nov; 41(11):1911-1926.e8. PubMed ID: 37802053
[TBL] [Abstract][Full Text] [Related]
60. Diffuse Intrinsic Pontine Glioma Cells Are Vulnerable to Mitotic Abnormalities Associated with BMI-1 Modulation.
Senthil Kumar S; Sengupta S; Zhu X; Mishra DK; Phoenix T; Dyer L; Fuller C; Stevenson CB; DeWire M; Fouladi M; Drissi R
Mol Cancer Res; 2020 Nov; 18(11):1711-1723. PubMed ID: 32801164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
